2017
SJR Q2
JCR Q4 · 1,8
7 matched articles
Journal detail
HIV Clinical Trials
- Publisher
- Taylor and Francis Ltd.
- Country
- United Kingdom · Western Europe
- Type
- journal
- ISSN
-
15284336
Integrated evaluation
Scopus side is Scimago SJR; WoS side is Master Journal List + JCR/JIF. Sources are matched on ISSN. WoS / JCR metrics are available for 1997 and later years only.
WoS / JCR data covers 1997 onward.
Scopus
Scopus · Scimago
- SJR 0,707
- Quartile Q2
- H-Index 0
- Cites/doc 0
- Docs (3y) 0
- Cites (3y) 0
Clarivate
Web of Science · JCR · 2019
- JCR Q Q4
- JIF 1,8
- 5Y JIF 1,4
- JCI —
Subject classification
Categories (SJR)
- Infectious Diseases Q3
- Pharmacology (medical) Q2
Areas
- Medicine
Yearly quartile comparison
Scimago (SJR) for all years; Clarivate (JCR / JIF / JCI) from 1997 onward. Latest year stays open; older years start collapsed.
WoS / JCR data covers 1997 onward.
| Year | SJR Q | JCR Q (1997+) | SJR | JIF (1997+) | 5Y JIF (1997+) | JCI (1997+) | JCI Q (1997+) | H-Index |
|---|---|---|---|---|---|---|---|---|
| 2019 | — | Q4 | — | 1,8 | 1,4 | — | — | — |
| 2018 | — | Q3 | — | 2,1 | 1,7 | — | — | — |
| 2017 | Q2 | Q4 | 0,707 | 1,4 | 1,6 | — | — | 0 |
| 2016 | Q2 | Q3 | 0,899 | 1,8 | 2,2 | — | — | 0 |
| 2015 | Q2 | Q3 | 1,027 | 2 | 1,9 | — | — | 0 |
| 2014 | Q1 | Q2 | 1,338 | 2,6 | 2,4 | — | — | 0 |
| 2013 | Q1 | Q3 | 1,096 | 2,1 | 2,1 | — | — | 0 |
| 2012 | Q2 | Q2 | 0,921 | 2,3 | 2 | — | — | 0 |
| 2011 | Q1 | Q3 | 1,021 | 1,6 | 1,9 | — | — | 0 |
| 2010 | Q1 | Q3 | 1,064 | 1,8 | 1,8 | — | — | 0 |
| 2009 | — | Q3 | — | 1,6 | 1,5 | — | — | — |
| 2008 | — | Q3 | — | 1,7 | 1,8 | — | — | — |
| 2007 | — | Q3 | — | 1,6 | — | — | — | — |
| 2006 | — | Q3 | — | 1,7 | — | — | — | — |
| 2005 | — | Q3 | — | 1,8 | — | — | — | — |
JCR category quartile history
JCR / JCI quartile by year and category. 1997 and later.
WoS / JCR data covers 1997 onward.
| Year | Category | Edition | JCR Q (1997+) | JCI Q (1997+) | Rank |
|---|---|---|---|---|---|
| 2019 | INFECTIOUS DISEASES | SCIE | Q4 | — | 75/92 |
| 2019 | PHARMACOLOGY & PHARMACY | SCIE | Q4 | — | 210/271 |
| 2018 | INFECTIOUS DISEASES | SCIE | Q3 | — | 65/89 |
| 2018 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 173/267 |
| 2017 | INFECTIOUS DISEASES | SCIE | Q4 | — | 75/88 |
| 2017 | PHARMACOLOGY & PHARMACY | SCIE | Q4 | — | 216/261 |
| 2016 | INFECTIOUS DISEASES | SCIE | Q3 | — | 63/84 |
| 2016 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 181/257 |
| 2015 | INFECTIOUS DISEASES | SCIE | Q3 | — | 55/83 |
| 2015 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 160/255 |
| 2014 | INFECTIOUS DISEASES | SCIE | Q2 | — | 37/78 |
| 2014 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 106/255 |
| 2013 | INFECTIOUS DISEASES | SCIE | Q3 | — | 48/72 |
| 2013 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 139/256 |
| 2012 | INFECTIOUS DISEASES | SCIE | Q3 | — | 42/70 |
| 2012 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 122/261 |
| 2011 | INFECTIOUS DISEASES | SCIE | Q3 | — | 52/70 |
| 2011 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 173/261 |
| 2010 | INFECTIOUS DISEASES | SCIE | Q4 | — | 45/58 |
| 2010 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 151/252 |
| 2009 | INFECTIOUS DISEASES | SCIE | Q4 | — | 45/57 |
| 2009 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 160/237 |
| 2008 | INFECTIOUS DISEASES | SCIE | Q4 | — | 41/51 |
| 2008 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 142/219 |
| 2007 | INFECTIOUS DISEASES | SCIE | Q4 | — | 40/50 |
| 2007 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 132/205 |
| 2006 | INFECTIOUS DISEASES | SCIE | Q4 | — | 38/47 |
| 2006 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 114/199 |
| 2005 | INFECTIOUS DISEASES | SCIE | Q4 | — | 33/43 |
| 2005 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 102/193 |